标题
Vascular toxicity associated with anti-angiogenic drugs
作者
关键词
-
出版物
CLINICAL SCIENCE
Volume 134, Issue 18, Pages 2503-2520
出版商
Portland Press Ltd.
发表日期
2020-09-29
DOI
10.1042/cs20200308
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
- (2020) Nicolas Palaskas et al. Journal of the American Heart Association
- The Epigenetic Profile of Tumor Endothelial Cells. Effects of Combined Therapy with Antiangiogenic and Epigenetic Drugs on Cancer Progression
- (2020) Oskar Ciesielski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Vascular toxic effects of cancer therapies
- (2020) Joerg Herrmann Nature Reviews Cardiology
- Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
- (2020) Alessia Mennitto et al. Journal of Clinical Medicine
- Drugging histone methyltransferases in cancer
- (2020) Laia Richart et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- VEGF-A promotes angiogenesis after acute myocardial infarction through increasing ROS production and enhancing ER stress-mediated autophagy
- (2019) Jiang Zou et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer
- (2019) Kirstin Perdrizet et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury
- (2019) Karla B Neves et al. CARDIOVASCULAR RESEARCH
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions
- (2019) Nicholas J. Salgia et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Involvement of Extracellular Vesicles in Vascular-Related Functions in Cancer Progression and Metastasis
- (2019) Shinsuke Kikuchi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
- (2019) James Chih-Hsin Yang LANCET ONCOLOGY
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
- (2019) Haruhiro Saito et al. LANCET ONCOLOGY
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
- (2019) Xuan Jiang et al. Cancer Management and Research
- Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors
- (2019) Alexander J. Gallan et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Limitations of Anti-Angiogenic Treatment of Tumors
- (2019) Domenico Ribatti et al. Translational Oncology
- Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma – A retrospective study
- (2019) Nadya Jammal et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
- (2019) Alexandra S. Zimmer et al. Journal for ImmunoTherapy of Cancer
- A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
- (2019) Mansoor Raza Mirza et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- (2019) Kata P. Szilveszter et al. Frontiers in Immunology
- Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats
- (2019) Katrina M Mirabito Colafella et al. CARDIOVASCULAR RESEARCH
- The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors
- (2019) Harish Seethapathy et al. Clinical Journal of the American Society of Nephrology
- Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
- (2019) Ling Gao et al. Frontiers in Pharmacology
- Crosstalk Between Vascular Redox and Calcium Signaling in Hypertension Involves TRPM2 (Transient Receptor Potential Melastatin 2) Cation Channel
- (2019) Rhéure Alves-Lopes et al. HYPERTENSION
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
- (2019) Raluca Ioana Teleanu et al. Journal of Clinical Medicine
- Vasculitis associated with immune checkpoint inhibitors—a systematic review
- (2018) Anisha Daxini et al. CLINICAL RHEUMATOLOGY
- VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive ProcessesNovelty and Significance
- (2018) Karla B. Neves et al. HYPERTENSION
- The Janus Face of VEGF in Stroke
- (2018) Samuel Geiseler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future
- (2018) Baichun Yang et al. JOURNAL OF APPLIED TOXICOLOGY
- Shedding light on the cell biology of extracellular vesicles
- (2018) Guillaume van Niel et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Tumor Therapy Remixed—An Update on the Use of Small-Molecule Drugs in Combination Therapies
- (2018) Martina Gatzka Cancers
- Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors
- (2018) Stephen J H Dobbin et al. HEART
- Immune checkpoint inhibitors and cardiovascular toxicity
- (2018) Alexander R Lyon et al. LANCET ONCOLOGY
- Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
- (2018) Shakila Jabeen et al. OncoImmunology
- The Methylation Status of the Epigenome: Its Emerging Role in the Regulation of Tumor Angiogenesis and Tumor Growth, and Potential for Drug Targeting
- (2018) Luciano Pirola et al. Cancers
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil
- (2017) Manami Katoh et al. International Heart Journal
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
- (2017) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis
- (2017) Hui Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
- (2017) Arun Sharma et al. Science Translational Medicine
- Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity
- (2017) Odessa Schillaci et al. Scientific Reports
- Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy
- (2016) Emiliano Calvo et al. CANCER TREATMENT REVIEWS
- Mechanisms and regulation of endothelial VEGF receptor signalling
- (2016) Michael Simons et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Cardiovascular Toxic Effects of Targeted Cancer Therapies
- (2016) Javid J. Moslehi NEW ENGLAND JOURNAL OF MEDICINE
- Functions of PARylation in DNA Damage Repair Pathways
- (2016) Huiting Wei et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Etiology of angiogenesis inhibition-related hypertension
- (2015) Stephanie Lankhorst et al. CURRENT OPINION IN PHARMACOLOGY
- Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension
- (2015) Anna M.J. Thijs et al. JOURNAL OF HYPERTENSION
- Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
- (2015) Eiki Ichihara et al. Journal of Thoracic Oncology
- 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study
- (2015) Manuela Quaresma et al. LANCET
- C/EBPβ and Nuclear Factor of Activated T Cells Differentially Regulate Adamts-1 Induction by Stimuli Associated with Vascular Remodeling
- (2015) Jorge Oller et al. MOLECULAR AND CELLULAR BIOLOGY
- Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma
- (2015) Ni Chen et al. Molecular Cancer
- Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome
- (2014) Heather Yvonne Small et al. CANADIAN JOURNAL OF CARDIOLOGY
- Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy
- (2014) Giuseppe Bronte et al. Expert Opinion On Drug Safety
- Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib
- (2014) Stephanie Lankhorst et al. HYPERTENSION
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer
- (2014) Labib Imran Faruque et al. PLoS One
- Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis
- (2014) Pei-Yuan Zuo et al. PLoS One
- Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress
- (2013) Stephanie Lankhorst et al. ANTIOXIDANTS & REDOX SIGNALING
- Oxidative stress in angiogenesis and vascular disease
- (2013) Y.-W. Kim et al. BLOOD
- Inhibition of Histone Demethylase JMJD1A Improves Anti-Angiogenic Therapy and Reduces Tumor-Associated Macrophages
- (2013) T. Osawa et al. CANCER RESEARCH
- Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents
- (2013) Gabriel Limaverde-Sousa et al. CANCER TREATMENT REVIEWS
- Aflibercept and Its Role in the Treatment of Colorectal Cancer--Letter
- (2013) F. A. Sinicrope et al. CLINICAL CANCER RESEARCH
- Endothelin Antagonism and Its Role in the Treatment of Hypertension
- (2013) Rebecca C. Moorhouse et al. CURRENT HYPERTENSION REPORTS
- Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans
- (2013) Anna M.J. Thijs et al. HYPERTENSION
- Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety
- (2013) Stephan Winnik et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors
- (2013) Franziska Stehle et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IL-17 mediates resistance to anti-VEGF therapy
- (2013) Eleni Maniati et al. NATURE MEDICINE
- EFFECTS OF INTRAVITREAL INJECTION OF BEVACIZUMAB ON INFLAMMATORY CYTOKINES IN THE VITREOUS WITH PROLIFERATIVE DIABETIC RETINOPATHY
- (2013) Yukihiko Suzuki et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
- (2013) Steven M. Bair et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment
- (2013) Hala Ahmadieh et al. Biomed Research International
- Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension
- (2012) Peter Kruzliak et al. ANGIOGENESIS
- Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
- (2012) John H. Strickler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity
- (2012) Mohammad Mohammadzadeh et al. CELL STRESS & CHAPERONES
- Microparticles: biomarkers and beyond
- (2012) Dylan Burger et al. CLINICAL SCIENCE
- Cancer drugs and the heart: importance and management
- (2012) T. M. Suter et al. EUROPEAN HEART JOURNAL
- Mechanism of hypertension and proteinuria during angiogenesis inhibition
- (2012) Stephanie Lankhorst et al. JOURNAL OF HYPERTENSION
- Cardiovascular and Systemic MicrovascularEffects of Anti-Vascular Endothelial Growth Factor Therapy for Cancer
- (2012) J. Todd Belcik et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ranibizumab for Diabetic Macular Edema
- (2012) Quan Dong Nguyen et al. OPHTHALMOLOGY
- Redox balance dynamically regulates vascular growth and remodeling
- (2012) Shyamal C. Bir et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Regulation of VEGF-induced endothelial cell migration by mitochondrial reactive oxygen species
- (2011) Youxue Wang et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma
- (2011) Anne Flörcken et al. ANTI-CANCER DRUGS
- The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System
- (2011) Mariëtte H.W. Kappers et al. HYPERTENSION
- Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress
- (2011) Mariëtte H.W. Kappers et al. HYPERTENSION
- Vasculitis Is an Antiangiogenic State
- (2011) I. E. Stillman et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Elevated Soluble Flt1 Inhibits Endothelial Repair in PR3-ANCA-Associated Vasculitis
- (2011) S. Le Roux et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
- (2010) Vishal Ranpura et al. ACTA ONCOLOGICA
- Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes
- (2010) F. A. B. Schutz et al. ANNALS OF ONCOLOGY
- Vascular endothelial growth factors and vascular permeability
- (2010) D. O. Bates CARDIOVASCULAR RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation
- (2010) Maija Bry et al. CIRCULATION
- Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2010) Thomas Eschenhagen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors
- (2010) Emily S. Robinson et al. HYPERTENSION
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
- (2010) Mariëtte H.W. Kappers et al. HYPERTENSION
- A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung
- (2010) Natasha B. Leighl et al. Journal of Thoracic Oncology
- Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker
- (2010) Emily S. Robinson et al. SEMINARS IN NEPHROLOGY
- Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients
- (2009) Chiara Giannarelli et al. CIRCULATION
- Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
- (2009) Carie S. Facemire et al. HYPERTENSION
- Vascular Endothelial Growth Factor (VEGF) Receptor-2 Tyrosine 1175 Signaling Controls VEGF-induced von Willebrand Factor Release from Endothelial Cells via Phospholipase C-γ1- and Protein Kinase A-dependent Pathways
- (2009) Yan Xiong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects
- (2009) Mariëtte HW Kappers et al. JOURNAL OF HYPERTENSION
- Nitric Oxide, Tetrahydrobiopterin, Oxidative Stress, and Endothelial Dysfunction in Hypertension
- (2008) Eberhard Schulz et al. ANTIOXIDANTS & REDOX SIGNALING
- Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability
- (2008) C. P. Hans et al. CARDIOVASCULAR RESEARCH
- Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
- (2008) N. Steeghs et al. CLINICAL CANCER RESEARCH
- Role of Endothelin-1 in Clinical Hypertension
- (2008) Neeraj Dhaun et al. HYPERTENSION
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Role of the Endothelium in the Vascular Effects of the Thrombin Receptor (Protease-Activated Receptor Type 1) in Humans
- (2008) Ingibjörg J. Guðmundsdóttir et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Protein kinase C-δ mediates von Willebrand factor secretion from endothelial cells in response to vascular endothelial growth factor (VEGF) but not histamine
- (2008) O. LORENZI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
- (2008) Masatoshi Jinnin et al. NATURE MEDICINE
- Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
- (2007) J.-J. Mourad et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation